AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-31. (Canceled).

32. (Previously presented) A method of increasing the transport in a neuron of a tetanus toxin or a fusion protein comprising a fragment C of the tetanus toxin, wherein the method comprises administering to the neuron a Brain Derived Neurotrophic Factor (BDNF), a Neurotrophin 4 (NT-4), or Glial-Derived Neurotrophic Factor (GDNF) in an amount sufficient to thereby increase the neuronal transport of the tetanus toxin or the fusion protein.

33. (Previously presented) The method according to claim 32, wherein Brain Derived Neurotrophic Factor (BDNF), Neurotrophin 4 (NT-4), or Glial-Derived Neurotrophic Factor (GDNF) thereby increases internalization of the tetanus toxin or fusion protein at a neuromuscular junction.

34-67. (Canceled).

68. (Previously Presented) The method according to claim 32, wherein the tetanus toxin is administered with Brain Derived Neurotrophic Factor (BDNF).

69. (Previously Presented) The method according to claim 32, wherein the tetanus toxin is administered with Neurotrophin 4 (NT-4).

70. (Previously Presented) The method according to claim 32, wherein the tetanus toxin is administered with Glial-Derived Neurotrophic Factor (GDNF).

71. (Previously Presented) The method according to claim 32, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Brain Derived Neurotrophic Factor (BDNF).

72. (Previously Presented) The method according to claim 32, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Neurotrophin 4 (NT-4).

73. (Previously Presented) The method according to claim 32, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Glial-Derived Neurotrophic Factor (GDNF).

74. (Previously Presented) The method of claim 68 or 71, wherein the BDNF is injected into the *Levator auris longus* (LAL) muscle.

75. (Previously Presented) The method of claim 69 or 72, wherein the NT-4 is injected into the *Levator auris longus* (LAL) muscle.

76. (Previously Presented) The method of claim 70 or 73, wherein the GDNF is injected into the *Levator auris longus* (LAL) muscle.

77. (Previously Presented) The method of claim 68 or 71, wherein the BDNF is injected into the *gastrocnemeius* muscle.

78. (Previously Presented) The method of claim 69 or 72, wherein the NT-4 is injected into the *gastrocnemeius* muscle.

79. (Previously Presented) The method of claim 70 or 73, wherein the GDNF is injected into the *gastrocnemeius* muscle.

80. (Currently Amended) A method of increasing the transport in a neuron of a tetanus toxin or a fusion protein comprising a fragment C of the tetanus toxin, wherein the method comprises

a) administering to the neuron a tetanus toxin or a fusion protein comprising a fragment C; and

b) administering to the neuron a Brain Derived Neurotrophic Factor (BDNF), a Neurotrophin 4 (NT-4), or Glial-Derived Neurotrophic Factor (GDNF) in an amount sufficient to increase the neuronal transport of the tetanus toxin or the fusion protein,

~~wherein the tetanus toxin or a fusion protein comprising a fragment C may be administered before, after, or simultaneously with the administration of a Brain Derived Neurotrophic Factor (BDNF), a Neurotrophin 4 (NT-4), or Glial-Derived Neurotrophic Factor (GDNF)~~.

81. (Previously Presented) The method according to claim 80, wherein the tetanus toxin is administered with Brain Derived Neurotrophic Factor (BDNF).

82. (Previously Presented) The method according to claim 80, wherein the tetanus toxin is administered with Neurotrophin 4 (NT-4).

83. (Previously Presented) The method according to claim 80, wherein the tetanus toxin is administered with Glial-Derived Neurotrophic Factor (GDNF).

84. (Previously Presented) The method according to claim 80, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Brain Derived Neurotrophic Factor (BDNF).

85. (Previously Presented) The method according to claim 80, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Neurotrophin 4 (NT-4).

86. (Previously Presented) The method according to claim 80, wherein the fusion protein comprising a fragment C of the tetanus toxin is administered with Glial-Derived Neurotrophic Factor (GDNF).

87. (Previously Presented) The method of claim 81 or 84, wherein the BDNF is injected into the *Levator auris longus* (LAL) muscle.

88. (Previously Presented) The method of claim 82 or 85, wherein the NT-4 is injected into the *Levator auris longus* (LAL) muscle.

89. (Previously Presented) The method of claim 83 or 86, wherein the GDNF is injected into the *Levator auris longus* (LAL) muscle.

90. (Previously Presented) The method of claim 81 or 84, wherein the BDNF is injected into the *gastrocnemeius* muscle.

91. (Previously Presented) The method of claim 82 or 85, wherein the NT-4 is injected into the *gastrocnemeius* muscle.

92. (Previously Presented) The method of claim 83 or 86, wherein the GDNF is injected into the *gastrocnemeius* muscle.

93 (New) The method of claim 80, wherein the tetanus toxin or a fusion protein comprising a fragment C may be administered before, after, or simultaneously with the administration of a Brain Derived Neurotrophic Factor (BDNF), a Neurotrophin 4 (NT-4), or Glial-Derived Neurotrophic Factor (GDNF).